LQDA Stock — Liquidia Corporation

Liquidia Corporation (LQDA)

Updated October 16, 2026.

LQDA is a Stock. Total return is 209.5% over the past 8.2 years, 4.5 points ahead of SPY at 205.0%.

Liquidia Corporation is a biopharmaceutical company that develops and commercializes treatments for rare cardiopulmonary diseases, with lead product YUTREPIA, an inhaled formulation of treprostinil for pulmonary arterial hypertension and related conditions, along with existing products like Remodulin and proprietary PRINT particle engineering technology. The company does not currently distribute dividends. Liquidia appeals primarily to investors seeking exposure to early-stage pharmaceutical development and rare disease therapeutics rather than income-focused investors.

LQDA performance versus SPY

Price and return data through 2026-10-16.

Total return is 209.5% over the past 8.2 years, 4.5 points ahead of SPY at 205.0%. Over the past year its total return — price change plus distributions reinvested — is 48.2%. Its deepest 1-year drawdown was 71.5%.

LQDA key facts

Asset type

Stock

Asset class

Equity

Inception date

07/26/2018

Distribution frequency

None

Last close

$34.35 (as of 2026-10-16)

Market cap

$3,074,630,406

Average volume

4237458.0

Beta

0.61

Payout ratio

0.0%

P/E ratio

24.71

Forward P/E

10.5263

EPS

$1.39

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

LQDA risks and drawbacks

The deepest 1-year drawdown on record here is 71.5%.

Who may consider LQDA — and who may not

It is a weaker fit for investors who need monthly cash flow (LQDA does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on LQDA

• All tickers starting with L

Tagged: Pharmaceutical.

Frequently asked questions